Search

Ulcerative Colitis Drug Market

Ulcerative Colitis Drug Market Size by Type (Biologics, Corticosteroids, Immunomodulators, 5-Aminosalicylic Acid, Immunosuppressant, Biosimilars), Route of Administration (Oral, Injectable), Application, Distribution Channel, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-12521
  • Published Date: Aug, 2024
  • Pages: 236
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Global ulcerative colitis drug market is expected to reach USD 12.98 billion by 2033, at a CAGR of 5% from 2024 to 2033. Global ulcerative colitis drug market is witnessing a considerable growth owing to increasing prevalence rate and ongoing research and development activities. Due to modern lifestyle, people have changed their diets. They like to eat junk food, which affects the intestine and stomach, and due to this, the cases of ulcerative colitis have increased. Technological advancement also helps pharmaceutical companies develop new drugs. This helps manufacturers to know about the efficacy and side effects of the drug, easily remove its shortcomings, and launch a perfect drug in the market.

Market Overview:

Ulcerative colitis is an inflammatory bowel disease (IBD) of the large intestine. In this condition, the lining of the colon becomes inflamed and develops tiny open sores or ulcers that causes ulcers (sores) and long-lasting inflammation in the digestive tract. Ulcerative colitis can occur at any age in the lifeline, but it usually starts between the ages of 15 and 30. It tends to run in families. Some of the symptoms of ulcerative colitis are abdominal pain, diarrhoea with mucus, fatigue or tiredness, weight loss, loss of appetite, anaemia, elevated temperature, dehydration, and a constant urge to pass feces. Ulcerative colitis found worldwide but is most common in the United States, northern Europe, and England. Ulcerative colitis can be diagnosed through clinical evaluation, laboratory tests, imaging studies and biopsy. All these methods are adopted considering the severity of ulcerative colitis.

At present, there is no cure for ulcerative colitis, but some medications are available for the treatment of this disease. Several categories of drugs are available in the market in treating ulcerative colitis. The main focus of these drugs is to minimize & control the signs and symptoms of the disease. The treatment and medicines depend on the severity of the condition of the patient and location of ulcerative colitis. Drugs such as corticosteroids, immunomodulator drugs, biologics, and other medications are used to treat the ulcerative colitis effectively. Where medications failed to cure the ulcerative colitis, surgical method is often preferred to eliminate ulcerative colitis. However, it includes the removal of the entire colon and rectum (proctocolectomy); thus, many people avoid surgery and prefer the drugs to treat the ulcerative colitis. The most common ones are mercaptopurine (Purinethol, Purixan), azathioprine (Azasan, Imuran), and cyclosporine (Gengraf, Neoral, and Sandimmune). For many years, immunomodulators were not approved by the FDA to treat people with ulcerative colitis. However, this class of drugs was sometimes used off-label to treat people with ulcerative colitis. In 2018, the FDA approved the use of an immunomodulator for people with ulcerative colitis.

Ulcerative Colitis Drug Market Size 

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers
  • The emergence of biosimilars driving the growth of market 

The introduction of biosimilars has revolutionized the management of ulcerative colitis (UC). It is biological therapy used to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. These drugs are less costly than other drugs, which makes it more accessible in developing countries. In addition to this, many companies are focusing on the development of biosimilars for the treatment of ulcerative colitis, boosting the growth of the market. 

  • Growing prevalence of ulcerative colitis

The increasing global incidence of ulcerative colitis, driving the demand for drugs for the cure and treatment. During the study period of more than four decades (1963–2010), prevalence rates increased from 44 to 474 per 100,000, and annual incidence rates of ulcerative colitis increased from 4 to 18 per 100,000. In addition to this, the 2018 Impact of Inflammatory Bowel Disease in Canada report shows that Canada has among the highest prevalence of ulcerative colitis in the world. Thus, increasing incidences and prevalence of ulcerative colitis, demand for drugs has been increased across the globe. 

Restraints:
  • Side effects of ulcerative colitis drugs may impact the health 

Adverse effects of a drug used for the treatment of ulcerative colitis may affect the health of person, anticipated to hinder the market growth over the forecast period. Common side effects include rounding of the diabetes, face (moon face), acne, increased body hair, high blood pressure, cataracts, weight gain, and increased susceptibility to infections, glaucoma, muscle weakness, depression, irritability,insomnia, and thinning of the bones. The most severe complication from long term drug use is aseptic necrosis of the hip joints. 

Opportunities:
  • Opportunity to develop generic drugs for the treatment of ulcerative colitis

Ulcerative colitis’s branded medications, which are used for the procedure, are expensive. Many patients in the developing cannot afford these costly drugs for the treatment, and thus they avoid the treatment due to the high cost of drugs. Therefore, there is a potential opportunity in the market to develop the generic medication for the ulcerative colitis. Currently, many branded drug’s patents are near to expiration, which offers significant opportunities for the generic drug manufactures in the market. 

Challenges:
  • Limited awareness about the ulcerative colitis condition 

Ulcerative colitis (UC) is a lifelong disease progressing over time. Lack of public awareness may contribute to late diagnosis, tardy consultation of primary care physicians, and development of potentially preventable complications of the disease. Thus, limited knowledge about ulcerative colitis among the people may hinder the market growth over the forecast period. 

Segmentation Analysis:

The global ulcerative colitis drug market has been segmented based on type, route of administration, application, distribution channel, and regions.

  • The type segment is divided into biologics, corticosteroids, immunomodulators, 5-aminosalicylic acid, immunosuppressant, biosimilars, and others. Biologics accounted for the major market share of 43.32% and valued at USD 3.45 billion in 2023. Biologics is the most widely used drugs for the treatment of ulcerative colitis across the globe. Four biologics, in particular, are FDA approved for treating ulcerative colitis including Humira (adalimumab), Simponi (golimumab), Remicade (infliximab), and Entyvio (vedolizumab).
  • The route of administration segment is classified into oral and injectable. Oral segment is anticipated to grow at the highest CAGR of 5.4% over the forecast period. The growth is mainly attributed to increasing preference for oral route of administration over the injectables. An oral route of administration can be used alone in patients who prefer not to use enemas or suppositories to treat the ulcerative colitis. 
  • The distribution channel segment includes hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share of 46.2% in the year 2023, due to rise in the number of in-patient. 
  • The application segment is divided into proctosigmoiditis, ulcerative proctitis, pancolitis, left-sided colitis, acute severe ulcerative colitis, and others. Ulcerative proctitis segment accounted for the largest market share of 57.23% and valued at USD 4.56 billion in 2023. The high incidence rate of ulcerative proctitis, resulting in the high demand for ulcerative colitis drug in this segment. 
Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. The North America region emerged as the largest market for the ulcerative colitis drug market with a 44.3% share of the market revenue in 2023.

North America Ulcerative Colitis Drug Market Share in 2023 - 44.3%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

  • This is because North America is growing tremendously in terms of the healthcare industry. North America region has become the hub for the technological development and transformation of the industry. Due to the presence of several technological and pharmaceutical players in countries like Canada and the U.S., North America is projected to dominate the global ulcerative colitis drug market.
  • The Asia Pacific region is anticipated to project the growth at the highest CAGR of 7.9% over the forecast period in the global ulcerative colitis drug market. Ulcerative colitis is increasing in many parts of Asia with gender distribution and age of diagnosis similar to North America. In addition to this, growing health awareness among the consumers and rising healthcare expenditure in the region, further driving the growth of the market.  
Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global ulcerative colitis drug industry.

In August 2019, Salix Pharmaceuticals, a wholly-owned subsidiary of Bausch Health Companies Inc., announced that its affiliate has entered into licensing agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease (IBD) and ulcerative colitis.

In October 2019, Janssen Pharmaceutica, a subsidiary of Johnson & Johnson announced that the U.S. Food and Drug Administration’s (FDA) approval of STELARA (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.

List of Key Market Players:
  • Bausch Health Companies Inc. (Salix Pharmaceutical)
  • AbbVie Inc.
  • Johnson and Johnson
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Merck & Co.
  • Teva Pharmaceuticals Ltd.
  • Takeda Pharmaceuticals
  • Shire
  • Pfizer Inc.
Key Target Audience
  • Healthcare Institutes
  • Drug Manufacturers
  • Government Authorities and R&D Institutions
  • World Health Organization
  • Food and Drug Administration
  • Consulting And Research Firm

Report Description:

  • Global Ulcerative colitis drug Market, Industry Analysis, Trends, Analysis and Forecast, 2024 to 2033 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2023 is considered as the base year of the report. 2020 to 2022 are considered as the historic years and 2024 to 2033 are the forecast years. The global ulcerative colitis drug market is based on revenue (USD Million/Billion). The report incorporates the market study on the basis of revenue. The study covers the market share revenue/market share for each of the segments, regions and countries catering to global ulcerative colitis drug market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of ulcerative colitis drug and regions which are deduced and formulated on the basis of their growth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global ulcerative colitis drug market. This offers vital and in depth insights in order to depict the overall market scenario.
  • The report offers the detailed study for the company profiles of key organizations operating in the global ulcerative colitis drug market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario. 
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
  • Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which act as a key potential for the investors. 
  • Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global ulcerative colitis drug market is covered in order to comprehend the adoption rate and evaluate the market size.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the ulcerative colitis drug market was valued at USD 7.97 billion in 2023 and is anticipated to reach USD 12.98 billion by 2033.

Global ulcerative colitis drug market is growing at a CAGR of 5% during the forecast period 2024-2033.

The North America region emerged as the largest market for the ulcerative colitis drug.

Emergence of biosimilars is the key driving factor for the ulcerative colitis drug market. Also, the increasing global incidence of ulcerative colitis, driving the demand for drug market.

Side effects of ulcerative colitis drugs may hamper the market growth.

Development of generic drugs for the treatment of ulcerative colitis will provide huge opportunities to the market.

Key players are Bausch Health Companies Inc. (Salix Pharmaceutical), AbbVie Inc., Johnson and Johnson, Boehringer Ingelheim GmbH, Novartis AG, Merck & Co.

Get Your Report Customized

  • Further segmentation of the market on the basis of type, application, end use, product, technology, method, process and any other segment depending on the market
  • Segmentation on the basis of any specific country or region
  • Any segment can be classified on the basis of application
  • Application segment can be further divided on the basis of companies
  • The companies profiled are not limited, we can incorporate additional companies of your choice
  • We can split the company market share on the basis of product, application and region
  • Report can be prepared for any specific country/region/segment
  • Customers can be added on the basis of regions and countries
Request for Customization

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Type
          4.3.2. Market Attractiveness Analysis By Route of Administration
          4.3.3. Market Attractiveness Analysis By Distribution Channel
          4.3.4. Market Attractiveness Analysis By Application
          4.3.5. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Emergence of biosimilars driving the growth of market
          5.2.2. Growing prevalence of ulcerative colitis
    5.3. Restrains
          5.3.1. Side effects of ulcerative colitis drugs may impact the health
    5.4. Opportunities
          5.4.1. Opportunity to develop the generic drugs for the treatment of ulcerative colitis
    5.5. Challenges
          5.5.1. Limited awareness about the ulcerative colitis condition

6. Global Ulcerative Colitis Drug Market Analysis and Forecast, By Type
    6.1. Segment Overview
    6.2. Biologics
    6.3. Corticosteroids
    6.4. Immunomodulators
    6.5. 5-Aminosalicylic Acid
    6.6. Immunosuppressant
    6.7. Biosimilars
    6.8. Others

7. Global Ulcerative Colitis Drug Market Analysis and Forecast, By Route of Administration
    7.1. Segment Overview
    7.2. Oral
    7.3. Injectable

8. Global Ulcerative Colitis Drug Market Analysis And Forecast, By Distribution Channel
    8.1. Segment Overview
    8.2. Hospitals Pharmacy
    8.3. Online Pharmacy
    8.4. Retail Pharmacy

9. Global Ulcerative Colitis Drug Market Analysis and Forecast, By Application
    9.1. Segment Overview
    9.2. Proctosigmoiditis
    9.3. Ulcerative proctitis
    9.4. Pancolitis
    9.5. Left-sided colitis
    9.6. Acute severe ulcerative colitis
    9.7. Others

10. Global Ulcerative Colitis Drug Market Analysis and Forecast, By Regional Analysis
    10.1. Segment Overview
    10.2. North America
          10.2.1. U.S.
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Europe
          10.3.1. Germany
          10.3.2. France
          10.3.3. U.K.
          10.3.4. Italy
          10.3.5. Spain
    10.4. Asia-Pacific
          10.4.1. Japan
          10.4.2. China
          10.4.3. India
    10.5. South America
          10.5.1. Brazil
    10.6. Middle East and Africa
          10.6.1. UAE
          10.6.2. South Africa

11. Global Ulcerative Colitis Drug Market-Competitive Landscape
    11.1. Overview
    11.2. Market Share of Key Players in the Ulcerative Colitis Drug Market
          11.2.1. Global Company Market Share
          11.2.2. North America Company Market Share
          11.2.3. Europe Company Market Share
          11.2.4. APAC Company Market Share
    11.3. Competitive Situations and Trends
          11.3.1. Product Launches and Developments
          11.3.2. Partnerships, Collaborations, and Agreements
          11.3.3. Mergers & Acquisitions
          11.3.4. Expansions

12. Company Profiles
    12.1. Bausch Health Companies Inc. (Salix Pharmaceutical)
          12.1.1. Business Overview
          12.1.2. Company Snapshot
          12.1.3. Company Market Share Analysis
          12.1.4. Company Product Portfolio
          12.1.5. Recent Developments
          12.1.6. SWOT Analysis
    12.2. AbbVie Inc.
          12.2.1. Business Overview
          12.2.2. Company Snapshot
          12.2.3. Company Market Share Analysis
          12.2.4. Company Product Portfolio
          12.2.5. Recent Developments
          12.2.6. SWOT Analysis
    12.3. Johnson and Johnson
          12.3.1. Business Overview
          12.3.2. Company Snapshot
          12.3.3. Company Market Share Analysis
          12.3.4. Company Product Portfolio
          12.3.5. Recent Developments
          12.3.6. SWOT Analysis
    12.4. Boehringer Ingelheim GmbH
          12.4.1. Business Overview
          12.4.2. Company Snapshot
          12.4.3. Company Market Share Analysis
          12.4.4. Company Product Portfolio
          12.4.5. Recent Developments
          12.4.6. SWOT Analysis
    12.5. Novartis AG
          12.5.1. Business Overview
          12.5.2. Company Snapshot
          12.5.3. Company Market Share Analysis
          12.5.4. Company Product Portfolio
          12.5.5. Recent Developments
          12.5.6. SWOT Analysis
    12.6. Merck & Co.
          12.6.1. Business Overview
          12.6.2. Company Snapshot
          12.6.3. Company Market Share Analysis
          12.6.4. Company Product Portfolio
          12.6.5. Recent Developments
          12.6.6. SWOT Analysis
    12.7. Teva Pharmaceuticals Ltd.
          12.7.1. Business Overview
          12.7.2. Company Snapshot
          12.7.3. Company Market Share Analysis
          12.7.4. Company Product Portfolio
          12.7.5. Recent Developments
          12.7.6. SWOT Analysis
    12.8. Takeda Pharmaceuticals
          12.8.1. Business Overview
          12.8.2. Company Snapshot
          12.8.3. Company Market Share Analysis
          12.8.4. Company Product Portfolio
          12.8.5. Recent Developments
          12.8.6. SWOT Analysis
    12.9. Shire
          12.9.1. Business Overview
          12.9.2. Company Snapshot
          12.9.3. Company Market Share Analysis
          12.9.4. Company Product Portfolio
          12.9.5. Recent Developments
          12.9.6. SWOT Analysis
    12.10. Pfizer Inc.
          12.10.1. Business Overview
          12.10.2. Company Snapshot
          12.10.3. Company Market Share Analysis
          12.10.4. Company Product Portfolio
          12.10.5. Recent Developments
          12.10.6. SWOT Analysis

List of Table

1. Global Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

2. Global Biologics Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

3. Global Corticosteroids Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

4. Global Immunomodulators Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

5. Global 5-aminosalicylic acid Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

6. Global Immunosuppressant Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

7. Global Biosimilars Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

8. Global Others Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

9. Global Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

10. Global Oral Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

11. Global Injectable Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

12. Global Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

13. Global Hospitals Pharmacy Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

14. Global Online Pharmacy Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

15. Global Retail Pharmacy Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

16. Global Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

17. Global Proctosigmoiditis Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

18. Global Ulcerative proctitis Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

19. Global Pancolitis Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

20. Global Left-sided colitis Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

21. Global Acute severe ulcerative colitis Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

22. Global Others Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion)

23. Global Ulcerative Colitis Drug Market, By Region, 2020–2033 (USD Billion) 

24. Global Ulcerative Colitis Drug Market, By North America, 2020–2033 (USD Billion)

25. North America Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

26. North America Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

27. North America Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

28. North America Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

29. U.S. Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

30. U.S. Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

31. U.S. Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

32. U.S. Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

33. Canada Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

34. Canada Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

35. Canada Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

36. Canada Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

37. Mexico Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

38. Mexico Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

39. Mexico Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

40. Mexico Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

41. Europe Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

42. Europe Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

43. Europe Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

44. Europe Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

45. Germany Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

46. Germany Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

47. Germany Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

48. Germany Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

49. France Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

50. France Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

51. France Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

52. France Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

53. U.K. Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

54. U.K. Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

55. U.K. Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

56. U.K. Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

57. Italy Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

58. Italy Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

59. Italy Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

60. Italy Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

61. Spain Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

62. Spain Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

63. Spain Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

64. Spain Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

65. Asia Pacific Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

66. Asia Pacific Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

67. Asia Pacific Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

68. Asia Pacific Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

69. Japan Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

70. Japan Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

71. Japan Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

72. Japan Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

73. China Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

74. China Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

75. China Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

76. China Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

77. India Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

78. India Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

79. India Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

80. India Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

81. South America Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

82. South America Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

83. South America Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

84. South America Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

85. Brazil Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

86. Brazil Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

87. Brazil Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

88. Brazil Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

89. Middle East and Africa Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

90. Middle East and Africa Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

91. Middle East and Africa Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

92. Middle East and Africa Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

93. UAE Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

94. UAE Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

95. UAE Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

96. UAE Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

97. South Africa Ulcerative Colitis Drug Market, By Type, 2020–2033 (USD Billion)

98. South Africa Ulcerative Colitis Drug Market, By Route of Administration, 2020–2033 (USD Billion)

99. South Africa Ulcerative Colitis Drug Market, By Distribution Channel, 2020–2033 (USD Billion)

100. South Africa Ulcerative Colitis Drug Market, By Application, 2020–2033 (USD Billion)

List of Figures 

1. Global Ulcerative Colitis Drug Market Segmentation

2. Ulcerative Colitis Drug Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Ulcerative Colitis Drug Market Attractiveness Analysis By Type

9. Global Ulcerative Colitis Drug Market Attractiveness Analysis By Route of Administration

10. Global Ulcerative Colitis Drug Market Attractiveness Analysis By Distribution Channel

11. Global Ulcerative Colitis Drug Market Attractiveness Analysis By Application

12. Global Ulcerative Colitis Drug Market Attractiveness Analysis By Region

13. Global Ulcerative Colitis Drug Market: Dynamics

14. Global Ulcerative Colitis Drug Market Share by Type (2023 & 2033)

15. Global Ulcerative Colitis Drug Market Share By Route of Administration (2023 & 2033)

16. Global Ulcerative Colitis Drug Market Share By Distribution Channel (2023 & 2033)

17. Global Ulcerative Colitis Drug Market Share By Application (2023 & 2033)

18. Global Ulcerative Colitis Drug Market Share by Regions (2023 & 2033)

19. Global Ulcerative Colitis Drug Market Share by Company (2023)

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global ulcerative colitis drug market on the basis of below mentioned segments:

Global Ulcerative Colitis Drug Market by Type:

  • Biologics
  • Corticosteroids
  • Immunomodulators
  • 5-aminosalicylic acid
  • Immunosuppressant
  • Biosimilars
  • Others

Global Ulcerative Colitis Drug Market by Route of Administration:

  • Oral
  • Injectable

Global Ulcerative Colitis Drug Market by Distribution Channel:

  • Hospitals Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Global Ulcerative Colitis Drug Market by Application:

  • Proctosigmoiditis
  • Ulcerative proctitis
  • Pancolitis
  • Left-sided colitis
  • Acute severe ulcerative colitis
  • Others

Global Ulcerative Colitis Drug Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Ask for customization Request Sample Speak to analyst Inquire before buying

Flexible Purchase Options

  • Chapters of your choice
  • Quantitative Information for Historical & Forecasted Data
  • Regional/Country Level Reports
Request for Special Pricing

Get in touch with us

+1-315-215-1633

sales@thebrainyinsights.com

Our Clients

Why choose us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date